Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

One notable development is the progress of nipocalimab, a drug with potential applications across multiple autoimmune diseases. JNJ projects peak sales for nipocalimab to exceed $5 billion ...

In part 2, we discuss the challenge inherent in treating adolescents who have the disease and how nipocalimab—for which a biologics license application received a priority review designation ...

Summary: Entrepreneurs often grapple with the decision of whether to structure their business as a Company or a Limited Liability Partnership (LLP). Both offer the advantage of limited liability and ...

这项研究评估了在研疗法nipocalimab在广泛的抗体阳性（抗AChR、抗MuSK和抗LRP4）的全身性重症肌无力（gMG）成年患者中的疗效。研究达到主要终点 ...